| Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trialNieves et al., 2026 | Research | Human clinical trial, RCT | 2026 | Abaloparatide |
|---|
| Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in…Badran et al., 2026 | Research | Meta-analysis, RCT | 2026 | Tesamorelin |
|---|
| Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk…Bozkurt et al., 2026 | Research | Human clinical trial, RCT | 2026 | Survodutide |
|---|
| ClinicalTrials.gov registry search for KPV (Lys-Pro-Val) as an intervention, checked 14 November 2026ClinicalTrials.gov, 2026 | Regulatory / official | Clinical trial registry entry | 2026 | KPV |
|---|
| Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands PoliceMHRA, 2026 | Regulatory / official | — | 2026 | Retatrutide |
|---|
| Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of…Okada et al., 2026 | Research | Human observational | 2026 | GHRP-2 |
|---|
| Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2…Hsia et al., 2026 | Research | Human clinical trial, RCT | 2026 | Mazdutide |
|---|
| Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease…The Lancet, 2026 | Research | Human clinical trial, RCT | 2026 | Semaglutide |
|---|
| Elamipretide: First ApprovalShirley, 2026 | Research | Narrative review | 2026 | Elamipretide |
|---|
| Forsteo solution for injection in pre-filled pen (teriparatide): Summary of Product CharacteristicseMC, 2026 | Regulatory / official | — | 2026 | Teriparatide |
|---|
| GLP-1 medicines for weight loss and diabetes: what you need to knowMHRA, 2026 | Regulatory / official | Government guidance | 2026 | Liraglutide, Semaglutide, Tirzepatide |
|---|
| Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic…Wang et al., 2026 | Research | Animal-preclinical | 2026 | GHRP-6 |
|---|
| Guidance Note 8: A guide to what is a medicinal productMHRA, 2026 | Regulatory / official | Regulatory / legislative document | 2026 | GHK-Cu |
|---|
| Hormones and skin pigmentation: fundamentals and clinical relevance (English title as indexed by Europe PMC)Bohm, 2026 | Research | Narrative review | 2026 | Afamelanotide |
|---|
| Imcivree solution for injection (setmelanotide): Summary of Product CharacteristicsRhythm Pharmaceutical UK Ltd (company listed on eMC), 2026 | Regulatory / official | — | 2026 | Setmelanotide |
|---|
| Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157…Tham et al., 2026 | Research | Narrative review | 2026 | Thymosin beta-4 |
|---|
| Mazdutide versus placebo in Chinese adults with type 2 diabetesZhu et al., 2026 | Research | Human clinical trial, RCT | 2026 | Mazdutide |
|---|
| MHRA Products database: active substance index (A to Z), checked 14 November 2026Medicines and Healthcare products Regulatory Agency (MHRA), 2026 | Regulatory / official | — | 2026 | Afamelanotide, AOD-9604, BPC-157, CJC-1295, Elamipretide, Epithalon, GHRP-2, GHRP-6, Hexarelin, Ipamorelin, Kisspeptin, KPV, Mazdutide, MOTS-c, Selank, Semax, Survodutide, TB-500, Thymosin beta-4 |
|---|
| MHRA Products database: search for bremelanotide and VyleesiMedicines and Healthcare products Regulatory Agency (MHRA), 2026 | Regulatory / official | — | 2026 | PT-141 (Bremelanotide) |
|---|
| Oxytocin concentrate for solution for infusion: Summary of Product Characteristics, eMCeMC, 2026 | Regulatory / official | — | 2026 | Oxytocin |
|---|
| Semaglutide injection (weight-management product): Summary of Product Characteristics, eMCeMC, 2026 | Regulatory / official | — | 2026 | Semaglutide |
|---|
| Setmelanotide for the Treatment of Acquired Hypothalamic ObesityMiller et al., 2026 | Research | Human clinical trial, RCT | 2026 | Setmelanotide |
|---|
| Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched…Argente et al., 2026 | Research | Human clinical trial, Human observational | 2026 | Setmelanotide |
|---|
| Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease…Kaplan et al., 2026 | Research | Human clinical trial, RCT | 2026 | Survodutide |
|---|
| Survodutide Once Weekly for the Treatment of Adults with Obesityle Roux et al., 2026 | Research | Human clinical trial, RCT | 2026 | Survodutide |
|---|
| Survodutide Once Weekly in Adults with Obesity and Type 2 DiabetesWharton et al., 2026 | Research | Human clinical trial, RCT | 2026 | Survodutide |
|---|
| Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and…Yoon et al., 2026 | Research | Human observational | 2026 | MOTS-c |
|---|
| The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axisDominikowski et al., 2026 | Research | — | 2026 | AOD-9604 |
|---|
| Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair, A Scoping ReviewMcGuire et al., 2026 | Research | Scoping review | 2026 | TB-500 |
|---|
| Tirzepatide injection: Summary of Product Characteristics, eMCeMC, 2026 | Regulatory / official | — | 2026 | Tirzepatide |
|---|
| Treatment With Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical…Gao et al., 2026 | Research | Human clinical trial, RCT | 2026 | Mazdutide |
|---|
| Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3eBioMedicine, 2025 | Research | Animal-preclinical, In-vitro | 2025 | Cagrilintide |
|---|
| Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)Garvey et al., 2025 | Research | Human clinical trial, RCT | 2025 | Cagrilintide |
|---|
| Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with…DeSapri et al., 2025 | Research | Human clinical trial, Human observational | 2025 | Abaloparatide |
|---|
| Efficacy of thymosin alpha 1 for sepsis: a systematic review and meta-analysis of randomized controlled trialsGu et al., 2025 | Research | Meta-analysis, RCT, Systematic review | 2025 | Thymosin Alpha-1 |
|---|
| Eladynos solution for injection in pre-filled pen (abaloparatide): Summary of Product CharacteristicsTheramex Ireland Limited (marketing authorisation holder), 2025 | Regulatory / official | — | 2025 | Abaloparatide |
|---|
| Emerging Use of BPC-157 in Orthopaedic Sports Medicine, A Systematic ReviewVasireddi et al., 2025 | Research | Systematic review | 2025 | BPC-157 |
|---|
| FDA Grants Accelerated Approval to First Treatment for Barth SyndromeFDA, 2025 | Regulatory / official | — | 2025 | Elamipretide |
|---|
| Mazdutide: First ApprovalShirley, 2025 | Research | Narrative review | 2025 | Mazdutide |
|---|
| Multifunctionality and Possible Medical Application of the BPC 157 Peptide, Literature and Patent ReviewJozwiak et al., 2025 | Research | Narrative review | 2025 | BPC-157 |
|---|
| Once-Weekly Mazdutide in Chinese Adults with Obesity or OverweightJi et al., 2025 | Research | Human clinical trial, RCT | 2025 | Mazdutide |
|---|
| Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide with Promising PropertiesAraj et al., 2025 | Research | — | 2025 | Epithalon |
|---|
| PMDA medicinal product information: GHRP Kaken 100 Injection (pralmorelin hydrochloride), package insertPharmaceuticals and Medical Devices Agency (PMDA) et al., 2025 | Regulatory / official | — | 2025 | GHRP-2 |
|---|
| Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatideCosman et al., 2025 | Research | Human observational | 2025 | Abaloparatide |
|---|
| The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo…Wu et al., 2025 | Research | Human clinical trial, RCT | 2025 | Thymosin Alpha-1 |
|---|
| Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis…Tian et al., 2025 | Research | Meta-analysis, RCT, Systematic review | 2025 | Thymosin Alpha-1 |
|---|
| Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)Aronne et al., 2025 | Research | Human clinical trial, RCT | 2025 | Tirzepatide |
|---|
| Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)Packer et al., 2025 | Research | Human clinical trial, RCT | 2025 | Tirzepatide |
|---|
| Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA…Nature Medicine, 2025 | Research | Human clinical trial, RCT | 2025 | Tirzepatide |
|---|
| FDA Briefing Document, Pharmacy Compounding Advisory Committee: CJC-1295-Related Bulk Drug SubstancesFDA, 2024 | Regulatory / official | Regulatory / legislative document | 2024 | CJC-1295 |
|---|
| Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis…Karaa et al., 2024 | Research | Human clinical trial, RCT | 2024 | Elamipretide |
|---|
| Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension…Thompson et al., 2024 | Research | Human clinical trial | 2024 | Elamipretide |
|---|
| Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive…Rahaman et al., 2024 | Research | Animal-preclinical | 2024 | Thymosin beta-4 |
|---|
| The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a…Kluijver et al., 2024 | Research | Human observational | 2024 | Afamelanotide |
|---|
| Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a…Sanyal et al., 2024 | Research | Human clinical trial, RCT | 2024 | Retatrutide |
|---|
| Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire…Mills et al., 2023 | Research | Human clinical trial, RCT | 2023 | Kisspeptin |
|---|
| Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3…Karaa et al., 2023 | Research | Human clinical trial, RCT | 2023 | Elamipretide |
|---|
| Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity…Zeng et al., 2023 | Research | Human clinical trial, RCT | 2023 | Tirzepatide |
|---|
| Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesLincoff et al., 2023 | Research | Human clinical trial, RCT | 2023 | Semaglutide |
|---|
| The effects of kisspeptin on food intake in women with overweight or obesityIzzi-Engbeaya et al., 2023 | Research | Human clinical trial, RCT | 2023 | Kisspeptin |
|---|
| Thymosin alpha1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical ApplicationTao et al., 2023 | Research | Narrative review | 2023 | Thymosin Alpha-1 |
|---|
| Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 TrialJastreboff et al., 2023 | Research | Human clinical trial, RCT | 2023 | Retatrutide |
|---|
| 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic…Sosne et al., 2022 | Research | RCT, Human clinical trial | 2022 | Thymosin beta-4 |
|---|
| Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical…Thurston et al., 2022 | Research | Human clinical trial, RCT | 2022 | Kisspeptin |
|---|
| Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl…Haqq et al., 2022 | Research | Human clinical trial, RCT | 2022 | Setmelanotide |
|---|
| Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)Jastreboff et al., 2022 | Research | Human clinical trial, RCT | 2022 | Tirzepatide |
|---|
| Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionWilding et al., 2022 | Research | Human clinical trial | 2022 | Semaglutide |
|---|
| A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of…Thompson et al., 2021 | Research | Human clinical trial, RCT | 2021 | Elamipretide |
|---|
| Afamelanotide (Scenesse): advice on prevention of phototoxicity in adult patients with erythropoietic…Scottish Medicines Consortium (SMC), 2021 | Regulatory / official | — | 2021 | Afamelanotide |
|---|
| Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotideArisi et al., 2021 | Research | Human observational | 2021 | Afamelanotide |
|---|
| Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic…Dieli-Conwright et al., 2021 | Research | Human observational, RCT | 2021 | MOTS-c |
|---|
| Freedom of Information response FOI 21/1237, Yellow Card reports for Melanotan II products (2011-2021) and…MHRA, 2021 | Regulatory / official | — | 2021 | Melanotan II |
|---|
| Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainLee et al., 2021 | Research | Human observational | 2021 | BPC-157, TB-500 |
|---|
| Intranasal Oxytocin in Children and Adolescents with Autism Spectrum DisorderSikich et al., 2021 | Research | Human clinical trial, RCT | 2021 | Oxytocin |
|---|
| MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle…Reynolds et al., 2021 | Research | Animal-preclinical, In-vitro | 2021 | MOTS-c |
|---|
| Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre…Lau et al., 2021 | Research | Human clinical trial, RCT | 2021 | Cagrilintide |
|---|
| Once-Weekly Semaglutide in Adults with Overweight or ObesityWilding et al., 2021 | Research | Human clinical trial, RCT | 2021 | Semaglutide |
|---|
| Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating…Sun et al., 2021 | Research | Animal-preclinical | 2021 | KPV |
|---|
| Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance StudyGilsenan et al., 2021 | Research | Human observational | 2021 | Teriparatide |
|---|
| A registered replication study on oxytocin and trustNature Human Behaviour, 2020 | Research | Human clinical trial, RCT | 2020 | Oxytocin |
|---|
| Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body…Sinha et al., 2020 | Research | Narrative review | 2020 | Sermorelin |
|---|
| Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC…Clement et al., 2020 | Research | Human clinical trial | 2020 | Setmelanotide |
|---|
| Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistWillard et al., 2020 | Research | In-vitro | 2020 | Tirzepatide |
|---|
| Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder, Two Randomized Phase 3 TrialsKingsberg et al., 2019 | Research | Human clinical trial, RCT | 2019 | PT-141 (Bremelanotide) |
|---|
| VYLEESI (bremelanotide injection), Prescribing Information / FDA approval documentation (NDA 210557)FDA, 2019 | Regulatory / official | — | 2019 | PT-141 (Bremelanotide) |
|---|
| ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal…Bone et al., 2018 | Research | Human clinical trial | 2018 | Abaloparatide |
|---|
| Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor DevelopmentFratangelo et al., 2018 | Research | Animal-preclinical, In-vitro, Narrative review | 2018 | Kisspeptin |
|---|
| Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis…Kendler et al., 2018 | Research | Human clinical trial, RCT | 2018 | Teriparatide |
|---|
| Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for…Cai et al., 2018 | Research | Human clinical trial | 2018 | Oxytocin |
|---|
| The efficacy of semax in the treatment of patients at different stages of ischemic strokeGusev et al., 2018 | Research | Human clinical trial | 2018 | Semax |
|---|
| 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals…le Roux et al., 2017 | Research | Human clinical trial, RCT | 2017 | Liraglutide |
|---|
| A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation…Abbara et al., 2017 | Research | Human clinical trial, RCT | 2017 | Kisspeptin |
|---|
| Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A…Miller et al., 2016 | Research | Human clinical trial, RCT | 2016 | Abaloparatide |
|---|
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)Marso et al., 2016 | Research | Human clinical trial, RCT | 2016 | Liraglutide |
|---|
| Selank Administration Affects the Expression of Some Genes Involved in GABAergic NeurotransmissionVolkova et al., 2016 | Research | Animal-preclinical | 2016 | Selank |
|---|
| A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementPi-Sunyer et al., 2015 | Research | Human clinical trial, RCT | 2015 | Liraglutide |
|---|
| Afamelanotide for Erythropoietic ProtoporphyriaLangendonk et al., 2015 | Research | Human clinical trial, RCT | 2015 | Afamelanotide |
|---|
| Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation…Abbara et al., 2015 | Research | Human clinical trial, RCT | 2015 | Kisspeptin |
|---|
| GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin RegenerationPickart et al., 2015 | Research | — | 2015 | GHK-Cu |
|---|
| Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyriaBiolcati et al., 2015 | Research | Human observational | 2015 | Afamelanotide |
|---|
| The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin…Lee et al., 2015 | Research | Animal-preclinical, In-vitro | 2015 | MOTS-c |
|---|
| Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial…Sosne et al., 2015 | Research | RCT, Human clinical trial | 2015 | Thymosin beta-4 |
|---|
| Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trialSosne et al., 2015 | Research | RCT, Human clinical trial | 2015 | Thymosin beta-4 |
|---|
| Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of…Federal Register, 2013 | Regulatory / official | Regulatory / legislative document | 2013 | Sermorelin |
|---|
| Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteersCabrales et al., 2013 | Research | Human clinical trial | 2013 | GHRP-6 |
|---|
| Safety and Tolerability of the Hexadecapeptide AOD9604 in HumansStier et al., 2013 | Research | Human clinical trial, RCT | 2013 | AOD-9604 |
|---|
| Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis…Schaible et al., 2013 | Research | Animal-preclinical | 2013 | KPV |
|---|
| The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH…Kinoshita et al., 2013 | Research | Human clinical trial | 2013 | GHRP-2 |
|---|
| Egrifta (tesamorelin), EPAR, Withdrawal of marketing-authorisation applicationEMA, 2012 | Regulatory / official | — | 2012 | Tesamorelin |
|---|
| A review of safety, side-effects and subjective reactions to intranasal oxytocin in human researchMacDonald et al., 2011 | Research | — | 2011 | Oxytocin |
|---|
| Melanotan-associated melanomaPaurobally et al., 2011 | Research | Case report / case series | 2011 | Melanotan II |
|---|
| A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy…Ruff et al., 2010 | Research | RCT, Human clinical trial | 2010 | TB-500, Thymosin beta-4 |
|---|
| The effect of thymosin treatment of venous ulcersGuarnera et al., 2010 | Research | RCT, Human clinical trial | 2010 | Thymosin beta-4 |
|---|
| A cosmetic anti-ageing product improves photoaged skin: a double-blind, randomized controlled trialWatson et al., 2009 | Research | Human clinical trial, RCT | 2009 | GHK-Cu |
|---|
| Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH…Veldhuis et al., 2009 | Research | Human clinical trial | 2009 | GHRP-2 |
|---|
| Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosisPituitary, 2009 | Research | Human clinical trial | 2009 | GHRP-6 |
|---|
| Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A…Yang et al., 2008 | Research | Meta-analysis, RCT | 2008 | Thymosin Alpha-1 |
|---|
| Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized…Zozulia et al., 2008 | Research | Human clinical trial | 2008 | Selank |
|---|
| Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel…Kannengiesser et al., 2008 | Research | Animal-preclinical | 2008 | KPV |
|---|
| PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationDalmasso et al., 2008 | Research | In-vitro, Animal-preclinical | 2008 | KPV |
|---|
| Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIVFalutz et al., 2007 | Research | Human clinical trial, RCT | 2007 | Tesamorelin |
|---|
| Teriparatide or alendronate in glucocorticoid-induced osteoporosisSaag et al., 2007 | Research | Human clinical trial, RCT | 2007 | Teriparatide |
|---|
| Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated…Korkushko et al., 2006 | Research | — | 2006 | Epithalon |
|---|
| Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a…Teichman et al., 2006 | Research | Human clinical trial, RCT | 2006 | CJC-1295 |
|---|
| Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat…Dolotov et al., 2006 | Research | Animal-preclinical | 2006 | Semax |
|---|
| Oxytocin increases trust in humansKosfeld et al., 2005 | Research | Human clinical trial, RCT | 2005 | Oxytocin |
|---|
| Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain…Eremin et al., 2005 | Research | Animal-preclinical | 2005 | Semax |
|---|
| Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific…Muller et al., 2001 | Research | Human clinical trial, RCT | 2001 | GHRP-6 |
|---|
| Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with…Neer et al., 2001 | Research | Human clinical trial, RCT | 2001 | Teriparatide |
|---|
| Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and…Arvat et al., 2001 | Research | Human clinical trial, RCT | 2001 | Hexarelin |
|---|
| The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment…Heffernan et al., 2001 | Research | Animal-preclinical | 2001 | AOD-9604 |
|---|
| The lipolytic action of human growth hormone fragment 177-191 in isolated rat adipocytesHeffernan et al., 2001 | Research | Animal-preclinical, In-vitro | 2001 | AOD-9604 |
|---|
| GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adultsPopovic et al., 2000 | Research | Human clinical trial | 2000 | GHRP-6 |
|---|
| Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exerciseWideman et al., 2000 | Research | Human clinical trial | 2000 | GHRP-2 |
|---|
| Cardiac effects of hexarelin in hypopituitary adultsBisi et al., 1999 | Research | Human clinical trial | 1999 | Hexarelin |
|---|
| Ghrelin is a growth-hormone-releasing acylated peptide from stomachKojima et al., 1999 | Research | Animal-preclinical, In-vitro | 1999 | GHRP-6 |
|---|
| Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human…Gobburu et al., 1999 | Research | Human clinical trial | 1999 | Ipamorelin |
|---|
| Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone…Prakash et al., 1999 | Research | Narrative review | 1999 | Sermorelin |
|---|
| Tyr-Ala-hexarelin, a synthetic octapeptide, possesses the same endocrine activities of hexarelin and GHRP-2 in…Arvat et al., 1999 | Research | Human clinical trial, RCT | 1999 | GHRP-2, Hexarelin |
|---|
| Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH…Pandya et al., 1998 | Research | Human clinical trial, RCT | 1998 | GHRP-6 |
|---|
| Growth hormone status during long-term hexarelin therapyRahim et al., 1998 | Research | Human clinical trial | 1998 | Hexarelin |
|---|
| Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly menVittone et al., 1997 | Research | Human clinical trial | 1997 | Sermorelin |
|---|
| Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing…Khorram et al., 1997 | Research | Human clinical trial, RCT | 1997 | Sermorelin |
|---|
| Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological…Klinger et al., 1996 | Research | Human clinical trial | 1996 | Hexarelin |
|---|
| Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical studyDorr et al., 1996 | Research | Human clinical trial | 1996 | Melanotan II |
|---|
| Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response studyMassoud et al., 1996 | Research | Human clinical trial, RCT | 1996 | Hexarelin |
|---|
| A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced…ClinicalTrials.gov | Regulatory / official | — | — | Cagrilintide |
|---|
| A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes…PMC | Research | — | — | Semaglutide |
|---|
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PCO-02 (BPC-157) in Healthy VolunteersClinicalTrials.gov | Regulatory / official | Clinical trial registry entry | — | BPC-157 |
|---|
| BNF-derived guidance on managing risks of oxytocin infusion (water intoxication/hyponatraemia)NHS Specialist Pharmacy Service | Regulatory / official | — | — | Oxytocin |
|---|
| Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety RisksFDA | Regulatory / official | — | — | BPC-157 |
|---|
| Combination of 5-aminolevulinic acid and GHK peptide for androgenetic alopeciaLee et al. | Research | Human clinical trial | — | GHK-Cu |
|---|
| Guidance on unlicensed medicinal products ("specials"), Guidance Note 14MHRA | Regulatory / official | Regulatory / legislative document | — | Sermorelin, Thymosin Alpha-1 |
|---|
| Liraglutide (weight-management product): Summary of Product Characteristics, eMCeMC | Regulatory / official | — | — | Liraglutide |
|---|
| Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 8-11 April 2024EMA | Regulatory / official | — | — | Semaglutide |
|---|
| Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire…Journal of Clinical Investigation | Research | Human clinical trial, RCT | — | PT-141 (Bremelanotide) |
|---|
| MHRA reminds healthcare professionals to advise patients of the side effects of GLP-1 agonists and to report…MHRA | Regulatory / official | — | — | Semaglutide |
|---|
| Oxytocin (Syntocinon), Obstetrics, clinical guidanceNHS (Right Decisions Service et al. | Regulatory / official | — | — | Oxytocin |
|---|
| Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusClinicalTrials.gov | Regulatory / official | Clinical trial registry entry | — | Ipamorelin |
|---|
| Semaglutide (Wegovy) approved to treat form of liver diseaseMHRA | Regulatory / official | — | — | Semaglutide |
|---|
| Topical GHK-Cu Gel for Acute Skin Wound Healing (trial registry entry)registered sponsor/investigator | Regulatory / official | Regulatory-clinical source | — | GHK-Cu |
|---|